IMRN

Immuron

1.82 USD
+0.00
0.00%
At close Mar 17, 4:00 PM EDT
1 day
0.00%
5 days
1.68%
1 month
-8.54%
3 months
-15.35%
6 months
-30.80%
Year to date
2.25%
1 year
-33.58%
5 years
-0.55%
10 years
-78.23%
 

About: Immuron Ltd is a commercial and clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.

Employees: 7

0
Funds holding %
of 7,372 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

0% less ownership

Funds ownership: 0% [Q3] → 0% (-0%) [Q4]

64% less capital invested

Capital invested by funds: $29.2K [Q3] → $10.5K (-$18.8K) [Q4]

67% less funds holding

Funds holding: 3 [Q3] → 1 (-2) [Q4]

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 2

Research analyst outlook

We haven’t received any recent analyst ratings for IMRN.

Financial journalist opinion

Neutral
GlobeNewsWire
1 week ago
Immuron and Calmino join up to treat Irritable Bowel Syndrome (IBS)
MELBOURNE, Australia, March 05, 2025 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce it has entered into an exclusive distribution agreement for the territories of Australia and New Zealand. Immuron will launch ProIBS® for the treatment of symptoms related to IBS in the retail pharmacy sales channel. Immuron has been a leader in digestive health in Australia for many years. ProIBS® will join Immuron's product portfolio which includes the rapidly growing Travelan® brand building on the premium efficacy product range that will deliver better outcomes for consumers that Pharmacists will love to recommend.
Immuron and Calmino join up to treat Irritable Bowel Syndrome (IBS)
Neutral
GlobeNewsWire
1 month ago
Immuron Travelan® continued strong sales growth
Sales Highlights: Global December 2024 Quarter AUD$2.5 million up 70% on prior quarter, up 249% on pcp December 2024 Half Year AUD$4.0 million up 70% on pcp Australia December 2024 Quarter AUD$1.9 million up 83% on prior quarter, up 314% on pcp December 2024 Half Year AUD$2.9 million up 54% on pcp North America December 2024 Quarter AUD$0.7 million up 43% on prior quarter, up 141% on pcp December 2024 Half Year AUD$1.1 million up 130% on pcp MELBOURNE, Australia, Jan. 17, 2025 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce continued strong sales growth (unaudited) of Travelan®, an over-the-counter immune supplement that targets pathogenic bacteria and the toxins they produce in the gastrointestinal (GI) tract. Flavio Palumbo, Chief Commercial Officer said, “We are achieving strong growth in both Australia and North America reflecting the core ranging we secured in another nine pharmacy banner groups in Australia, distribution in ten pharmacy/grocery retailers in Canada and sales growth on amazon.com in the US.
Immuron Travelan® continued strong sales growth
Neutral
GlobeNewsWire
2 months ago
Immuron Announces New Research Collaboration targeting Antimicrobial Resistance
Highlights: New Research Collaboration w ith Monash University One proposal will target Antimicrobial Resistant Pathways to develop broad spectrum therapeutic drug products Second project proposal will focus on the Develop of new therapeutic drug candidates against Vancomycin-resistant enterococci (VRE) MELBOURNE, Australia, Jan. 15, 2025 (GLOBE NEWSWIRE) --  Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce a new research collaboration agreement with Monash University. The major objective of this research collaboration is to develop new therapeutic drug candidates which target antimicrobial resistant pathogens.
Immuron Announces New Research Collaboration targeting Antimicrobial Resistance
Neutral
GlobeNewsWire
2 months ago
Immuron Announces Travelan® Clinical Trial Update
Highlights: Travelan® (IMM-124E) Phase 2 Clinical Study Report submitted to the FDA Travelan® (IMM-124E) Phase 2 Clinical Study Statistically Significant Immunology Results Travelan® (IMM-124E) Phase 2 Clinical Study Statistically Significant Microbiome Responses Travelan® P2TD (n=866) Uniformed Services University field study randomized 776 subjects MELBOURNE, Australia, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce that it has submitted the Clinical Study Report to the U.S. Food and Drug Administration (FDA) for the recently completed Phase 2 study and will soon request an end of Phase 2 meeting which is a pre-cursor to proceeding to Phase 3. Travelan® (IMM-124E) Phase 2 Clinical Study NCT05933525: A Randomized, Double-blind, Placebo-controlled Trial Assessing the Efficacy of IMM-124E (Travelan®) in a Controlled Human Infection Model for Enterotoxigenic Escherichia Coli (ETEC) Immunology Statistically significant lower levels of IgA and IgG were observed for the subjects who received Travelan® compared to those who received the placebo, which may also reflect levels of exposure to ETEC antigen.
Immuron Announces Travelan® Clinical Trial Update
Neutral
GlobeNewsWire
3 months ago
Immuron CEO, Steven Lydeamore to Present at the Small Cap Growth Virtual Investor Conference December 5th
MELBOURNE, Australia, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to advise our Chief Executive Officer, Steven Lydeamore will be presenting at the Small Cap Growth Virtual Investor Conference hosted by VirtualInvestorConferences.com on Thursday 5th December 2024 (2.30pm U.S. Eastern time).
Immuron CEO, Steven Lydeamore to Present at the Small Cap Growth Virtual Investor Conference December 5th
Neutral
GlobeNewsWire
3 months ago
Immuron CEO, Steven Lydeamore presentation to 21st Virtual Investor Summit Microcap Event
MELBOURNE, Australia, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to advise our Chief Executive Officer, Steven Lydeamore presented early this morning at the 21st Virtual Investor Summit Microcap Event (November 21, US Eastern Time).
Immuron CEO, Steven Lydeamore presentation to 21st Virtual Investor Summit Microcap Event
Neutral
Accesswire
3 months ago
Immuron Limited to Present at November 21st Virtual Investor Summit Microcap Event
MELBOURNE, AUSTRALIA / ACCESSWIRE / November 18, 2024 / Immuron Limited (NASDAQ:IMRN) has one commercial product and two pipeline assets in three clinical programs for the treatment of gut mediated diseases. The company will be available for 1-on-1 meetings throughout the day in addition to their presentation.
Immuron Limited to Present at November 21st Virtual Investor Summit Microcap Event
Neutral
GlobeNewsWire
5 months ago
Immuron CEO, Steven Lydeamore participation in Maxim Virtual Healthcare Conference
MELBOURNE, Australia, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to advise our Chief Executive Officer, Steven Lydeamore will be participating in a fireside chat at the Maxim Virtual Healthcare Conference on Wednesday, 16th October 2024 (4.30pm U.S. Eastern time).
Immuron CEO, Steven Lydeamore participation in Maxim Virtual Healthcare Conference
Neutral
GlobeNewsWire
5 months ago
Immuron Travelan® continued strong sales growth
MELBOURNE, Australia, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce continued strong sales growth (unaudited) of Travelan®, an over-the-counter immune supplement that targets pathogenic bacteria and the toxins they produce in the gastrointestinal (GI) tract.
Immuron Travelan® continued strong sales growth
Neutral
GlobeNewsWire
5 months ago
NMRC Reports Results for Campylobacter Controlled Human Infection Model Study
MELBOURNE, Australia, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), is an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases. Following discussion with the US Naval Medical Research Command (NMRC), today the Company can announce that the NMRC has completed the interim analysis for the clinical evaluation of a new oral therapeutic targeting Campylobacter and Enterotoxigenic Escherichia coli (ETEC).
NMRC Reports Results for Campylobacter Controlled Human Infection Model Study
Charts implemented using Lightweight Charts™